These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 23363814)
1. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814 [TBL] [Abstract][Full Text] [Related]
2. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651 [TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212 [TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578 [TBL] [Abstract][Full Text] [Related]
6. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Johnston SR; Gómez H; Stemmer SM; Richie M; Durante M; Pandite L; Goodman V; Slamon D Breast Cancer Res Treat; 2013 Feb; 137(3):755-66. PubMed ID: 23283526 [TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681 [TBL] [Abstract][Full Text] [Related]
8. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802 [TBL] [Abstract][Full Text] [Related]
11. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221 [TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of pazopanib in patients with advanced cancer. Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Cristofanilli M; Johnston SR; Manikhas A; Gomez HL; Gladkov O; Shao Z; Safina S; Blackwell KL; Alvarez RH; Rubin SD; Ranganathan S; Redhu S; Trudeau ME Breast Cancer Res Treat; 2013 Jan; 137(2):471-82. PubMed ID: 23239151 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337 [TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]